JP2015505959A5 - - Google Patents

Download PDF

Info

Publication number
JP2015505959A5
JP2015505959A5 JP2014545002A JP2014545002A JP2015505959A5 JP 2015505959 A5 JP2015505959 A5 JP 2015505959A5 JP 2014545002 A JP2014545002 A JP 2014545002A JP 2014545002 A JP2014545002 A JP 2014545002A JP 2015505959 A5 JP2015505959 A5 JP 2015505959A5
Authority
JP
Japan
Prior art keywords
subject
cancer
inhibitor
group
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014545002A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015505959A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/068005 external-priority patent/WO2013086031A1/en
Publication of JP2015505959A publication Critical patent/JP2015505959A/ja
Publication of JP2015505959A5 publication Critical patent/JP2015505959A5/ja
Pending legal-status Critical Current

Links

JP2014545002A 2011-12-05 2012-12-05 癌を有する患者に治療を選択する方法 Pending JP2015505959A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161567085P 2011-12-05 2011-12-05
US61/567,085 2011-12-05
US201261728748P 2012-11-20 2012-11-20
US61/728,748 2012-11-20
PCT/US2012/068005 WO2013086031A1 (en) 2011-12-05 2012-12-05 Method of therapy selection for patients with cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017191195A Division JP2018054614A (ja) 2011-12-05 2017-09-29 癌を有する患者に治療を選択する方法

Publications (2)

Publication Number Publication Date
JP2015505959A JP2015505959A (ja) 2015-02-26
JP2015505959A5 true JP2015505959A5 (https=) 2016-01-28

Family

ID=48574842

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014545002A Pending JP2015505959A (ja) 2011-12-05 2012-12-05 癌を有する患者に治療を選択する方法
JP2017191195A Pending JP2018054614A (ja) 2011-12-05 2017-09-29 癌を有する患者に治療を選択する方法
JP2019182229A Pending JP2020024210A (ja) 2011-12-05 2019-10-02 癌を有する患者に治療を選択する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017191195A Pending JP2018054614A (ja) 2011-12-05 2017-09-29 癌を有する患者に治療を選択する方法
JP2019182229A Pending JP2020024210A (ja) 2011-12-05 2019-10-02 癌を有する患者に治療を選択する方法

Country Status (4)

Country Link
US (1) US20140273006A1 (https=)
EP (1) EP2788752B1 (https=)
JP (3) JP2015505959A (https=)
WO (1) WO2013086031A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016502974A (ja) * 2012-12-07 2016-02-01 ザ ジェネラル ホスピタル コーポレイション Ｐｉ３ｋ／ａｋｔ阻害剤化合物とｈｅｒ３／ｅｇｆｒ阻害剤化合物との組み合わせ及び高増殖性疾患の治療におけるその使用
MX2015010854A (es) * 2013-03-14 2016-07-20 Genentech Inc Combinaciones de un compuesto inhibidor de mek con un compuesto inhibidor de her3/egfr y metodos de uso.
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
EP3107578A2 (en) * 2014-02-20 2016-12-28 Merrimack Pharmaceuticals, Inc. Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
WO2016011558A1 (en) * 2014-07-23 2016-01-28 Ontario Institute For Cancer Research Systems, devices and methods for constructing and using a biomarker
CN107003300B (zh) * 2014-12-12 2020-02-07 凯尔科迪股份有限公司 测量erbb信号传导通路活性以诊断和治疗癌症患者的方法
ES3007999T3 (en) * 2015-04-21 2025-03-21 Genentech Inc Compositions and methods for prostate cancer analysis
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
HK1249866A1 (zh) * 2015-06-29 2018-11-16 豪夫迈‧罗氏有限公司 用他塞利昔布进行治疗的方法
EP3363911B1 (en) * 2015-10-14 2024-09-25 Nitto Boseki Co., Ltd. Method for determining drug-sensitive human breast cancer cells by analysis method in which measurement of activity of two types of protein kinase is used
KR20190015360A (ko) * 2016-05-31 2019-02-13 네스텍 소시에테아노님 Ｈｅｒ2 및 ｈｅｒ3 경로 아형 분류를 기반으로 한, 유방암 환자에 대한 약물 치료법의 선택 방법
US20180117029A1 (en) * 2016-11-03 2018-05-03 Beth Israel Deaconess Medical Center, Inc. Targeting Metabolic Vulnerability in Triple-Negative Breast Cancer
MX2019011769A (es) 2017-04-03 2019-11-07 Hoffmann La Roche Anticuerpos que se unen a steap-1.
CN113683700B (zh) * 2017-06-22 2023-05-02 北海康成（北京）医药科技有限公司 预测食管癌对抗erbb3抗体治疗的应答的方法和试剂盒
WO2020081956A1 (en) * 2018-10-18 2020-04-23 Medimmune, Llc Methods for determining treatment for cancer patients
KR102267593B1 (ko) * 2018-10-19 2021-06-21 주식회사 프로티나 Her2 및 her3의 헤테로다이머를 표적으로 하는 약물 및 이의 스크리닝 방법
CN111888487B (zh) * 2020-09-04 2022-05-17 山西医科大学 肿瘤靶向型光声成像引导多阶段治疗纳米探针及制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532138A (en) 1990-04-26 1996-07-02 Behringwerke Ag Method and kits for determining peroxidatively active catalysts
US5332662A (en) 1992-07-31 1994-07-26 Syntex (U.S.A.) Inc. Methods for determining peroxidatively active substances
WO1995006877A1 (en) 1993-09-03 1995-03-09 Behringwerke Ag Fluorescent oxygen channeling immunoassays
AU2005265214A1 (en) * 2004-06-21 2006-01-26 Exelixis, Inc. P4HAS as modifiers of the IGFR pathway and methods of use
NZ575827A (en) 2006-09-21 2012-02-24 Prometheus Lab Inc Antibody-based arrays for detecting multiple signal transducers in rare circulating cells
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
EP2179291B1 (en) * 2007-07-13 2014-10-22 Nestec S.A. Drug selection for lung cancer therapy using antibody-based arrays
EP2235536A4 (en) * 2007-12-20 2011-05-04 Lab Corp America Holdings HER-2-DIAGNOSTIC PROCEDURE
AU2009219437B2 (en) 2008-02-25 2014-10-16 Nestec S.A. Drug selection for breast cancer therapy using antibody-based arrays
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
NZ596468A (en) 2009-05-14 2013-11-29 Nestec Sa Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
JP5795311B2 (ja) 2009-07-15 2015-10-14 ネステク ソシエテ アノニム 抗体ベースのアレイを使用する胃癌療法のための薬物選択
DK2491385T3 (en) 2009-10-20 2017-08-28 Diatech Holdings Inc PROXIMITY-MEDIED ASSAYS FOR DETECTING ONCOGEN FUSION PROTEINS
BR112012017084A2 (pt) * 2010-01-12 2016-04-12 Nestec Sa métodos para previsão de resposta de câncer de mama triplo-negativo à terapia
US20110217701A1 (en) * 2010-03-03 2011-09-08 Carter Scott L Prognostic Marker for Endometrial Carcinoma
SG191230A1 (en) * 2010-12-23 2013-07-31 Nestec Sa Drug selection for malignant cancer therapy using antibody-based arrays
EP2681552A2 (en) * 2011-03-02 2014-01-08 Nestec S.A. Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures

Similar Documents

Publication Publication Date Title
JP2015505959A5 (https=)
Cohen Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)-and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC)
Leto et al. Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
Qi et al. Expression features of CXCR5 and its ligand, CXCL13 associated with poor prognosis of advanced colorectal cancer
Grünwald et al. Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma
EA201200025A1 (ru) Биомаркеры и способы определения эффективности анти-egfr антител для лечения злокачественного новообразования
Groen et al. A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)
RU2012134390A (ru) Способы предсказания ответа трижды негативного рака молочной железы на терапию
RU2017125053A (ru) Терапевтические, диагностические и прогностические способы для рака мочевого пузыря
Skoura et al. Role of positron emission tomography in the early prediction of response to chemotherapy in patients with non–small-cell lung cancer
RU2012109556A (ru) Биологические маркеры для мониторирования ответа пациента на антагонисты vegf
Machiels et al. Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN)
Bencsikova et al. Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view
Peng et al. Optimize the cycle of neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: a propensity score matching analysis
Peták et al. Integrating molecular diagnostics into anticancer drug discovery
JP2014533960A5 (https=)
Milella et al. EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy
Hatch et al. Blood‐based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)
Dziadziuszko et al. Epidermal growth factor receptor (EGFR) inhibitors and derived treatments
Cetin et al. Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents
Sudhindra et al. Biomarkers, prediction, and prognosis in non–small-cell lung cancer: a platform for personalized treatment
RU2015140573A (ru) Способы и композиции для обнаружения и лечения устойчивого к лекарственным средствам мутанта акт
Baselga et al. Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788
Moldvay Personalized treatment in non-small cell lung cancer: from diagnostics to therapy
EP2954068A1 (en) Drug selection for non-small cell lung cancer therapy